BIIB or ENZ or NCNA
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileENZ’s FA Score has 2 green FA rating(s), and NCNA’s FA Score reflects 0 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- ENZ’s FA Score: 2 green, 3 red.
- NCNA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 5 TA indicator(s) are bullish while ENZ’s TA Score has 4 bullish TA indicator(s), and NCNA’s TA Score reflects 2 bullish TA indicator(s).
- BIIB’s TA Score: 5 bullish, 5 bearish.
- ENZ’s TA Score: 4 bullish, 3 bearish.
- NCNA’s TA Score: 2 bullish, 7 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +0.19% price change this week, while ENZ (@Medical Specialties) price change was 0.00% , and NCNA (@Biotechnology) price fluctuated -36.03% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.20%. For the same industry, the average monthly price growth was -1.54%, and the average quarterly price growth was -7.79%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.62%. For the same industry, the average monthly price growth was -3.92%, and the average quarterly price growth was -1.88%.
The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was -3.08%, and the average quarterly price growth was -10.41%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 23, 2025.
ENZ is expected to report earnings on Jun 16, 2025.
NCNA is expected to report earnings on Mar 20, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+3.20% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Medical Specialties (+5.62% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Biotechnology (+8.19% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | ENZ | NCNA | |
| Capitalization | 31.3B | 64M | 3.33M |
| EBITDA | 2.04B | -16.29M | -29.33M |
| Gain YTD | -22.286 | -56.069 | -53.773 |
| P/E Ratio | 26.95 | 208.33 | N/A |
| Revenue | 9.84B | 32.8M | 0 |
| Total Cash | 1.05B | 60.2M | 11.4M |
| Total Debt | 7.34B | 7.18M | 221K |
BIIB | ENZ | NCNA | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 56 | 50 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 4 Undervalued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 67 | 94 | 97 | |
PRICE GROWTH RATING 1..100 | 65 | 96 | 97 | |
P/E GROWTH RATING 1..100 | 96 | 10 | 100 | |
SEASONALITY SCORE 1..100 | 85 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ENZ's Valuation (4) in the Biotechnology industry is somewhat better than the same rating for BIIB (50) and is somewhat better than the same rating for NCNA (50). This means that ENZ's stock grew somewhat faster than BIIB’s and somewhat faster than NCNA’s over the last 12 months.
ENZ's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100) and is in the same range as NCNA (100). This means that ENZ's stock grew similarly to BIIB’s and similarly to NCNA’s over the last 12 months.
BIIB's SMR Rating (67) in the Biotechnology industry is in the same range as ENZ (94) and is in the same range as NCNA (97). This means that BIIB's stock grew similarly to ENZ’s and similarly to NCNA’s over the last 12 months.
BIIB's Price Growth Rating (65) in the Biotechnology industry is in the same range as ENZ (96) and is in the same range as NCNA (97). This means that BIIB's stock grew similarly to ENZ’s and similarly to NCNA’s over the last 12 months.
ENZ's P/E Growth Rating (10) in the Biotechnology industry is significantly better than the same rating for BIIB (96) and is significantly better than the same rating for NCNA (100). This means that ENZ's stock grew significantly faster than BIIB’s and significantly faster than NCNA’s over the last 12 months.
| BIIB | ENZ | NCNA | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 62% | 11 days ago 72% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 68% | 11 days ago 89% | 3 days ago 90% |
| Momentum ODDS (%) | 3 days ago 60% | 11 days ago 81% | 3 days ago 84% |
| MACD ODDS (%) | 3 days ago 45% | 11 days ago 76% | 3 days ago 88% |
| TrendWeek ODDS (%) | 3 days ago 53% | 11 days ago 71% | 3 days ago 89% |
| TrendMonth ODDS (%) | 3 days ago 70% | 11 days ago 85% | 3 days ago 90% |
| Advances ODDS (%) | 14 days ago 54% | 14 days ago 68% | 12 days ago 79% |
| Declines ODDS (%) | 12 days ago 69% | 24 days ago 82% | 3 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 57% | 11 days ago 58% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 64% | N/A | 3 days ago 90% |
BIIB and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIIB has been loosely correlated with OGN. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BIIB jumps, then OGN could also see price increases.
| Ticker / NAME | Correlation To BIIB | 1D Price Change % | ||
|---|---|---|---|---|
| BIIB | 100% | -0.56% | ||
| OGN - BIIB | 49% Loosely correlated | +0.66% | ||
| AMGN - BIIB | 46% Loosely correlated | +0.36% | ||
| NVS - BIIB | 44% Loosely correlated | +0.87% | ||
| PFE - BIIB | 42% Loosely correlated | +0.61% | ||
| AZN - BIIB | 36% Loosely correlated | +0.03% | ||
More | ||||
ENZ and
Correlation & Price change
A.I.dvisor tells us that ENZ and SINT have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ENZ and SINT's prices will move in lockstep.
| Ticker / NAME | Correlation To ENZ | 1D Price Change % | ||
|---|---|---|---|---|
| ENZ | 100% | N/A | ||
| SINT - ENZ | 30% Poorly correlated | -5.15% | ||
| QIPT - ENZ | 27% Poorly correlated | -1.87% | ||
| CRL - ENZ | 27% Poorly correlated | -0.95% | ||
| MASS - ENZ | 26% Poorly correlated | +3.44% | ||
| SIBN - ENZ | 26% Poorly correlated | +0.14% | ||
More | ||||
NCNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NCNA has been closely correlated with RNAC. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then RNAC could also see price increases.
| Ticker / NAME | Correlation To NCNA | 1D Price Change % | ||
|---|---|---|---|---|
| NCNA | 100% | -15.37% | ||
| RNAC - NCNA | 93% Closely correlated | -1.83% | ||
| AGEN - NCNA | 93% Closely correlated | -4.26% | ||
| SNPX - NCNA | 92% Closely correlated | +1.11% | ||
| ALLR - NCNA | 86% Closely correlated | +5.61% | ||
| NRXP - NCNA | 85% Closely correlated | N/A | ||
More | ||||